Mucopolysaccharidosis (MPS) Treatment Market Size to Exceed USD 5.39 Bn by 2032

The Mucopolysaccharidosis (MPS) Treatment Market, estimated at USD 2.75 Bn in 2025, is expected to exhibit a CAGR of 10.1% and reach USD 5.39 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focused on adopting inorganic growth strategies such as collaborations, which will drive the global mucopolysaccharidosis (MPS) treatment market growth. For instance, in August 2020, Sarepta Therapeutics, Inc., a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, U.S. and The University of Florida,  a public land-grant research university in Gainesville, Florida, announced a strategic collaboration to enable cutting-edge research for novel genetic medicines for the treatment of rare genetic diseases such as mucopolysaccharidosis.

Global Mucopolysaccharidosis (MPS) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has had a negative impact on the overall healthcare system globally. Some of the key effects include:

Strain on Healthcare Infrastructure: The rapid spread of COVID-19 strained healthcare facilities, leading to overwhelmed hospitals, shortages of medical supplies, and challenges in providing adequate care to patients.

Reprioritization of Resources: Healthcare systems had to redirect resources and personnel towards COVID-19 response, potentially causing delays or disruptions in non-emergency medical services and treatments.

Impact on Non-COVID Medical Services: Many non-COVID medical services, including elective procedures and routine check-ups, were postponed or canceled to allocate resources to COVID-19 care.

Global Mucopolysaccharidosis (MPS) Treatment Market: Key Developments

In July 2020, Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company that develops  gene and cell therapies for life-threatening diseases, announced that two ongoing MPS III Phase 1/2 clinical trials of its investigational adeno-associated virus (AAV)-based gene therapies, ABO-102 and ABO-101, have showed positive effects on the patients, with additional enrollment programs.

As per an article published in PLOS One, in May 2021, it has been observed that enzyme replacement therapy (ERT) is the primary treatment for mucopolysaccharidosis type-II (hunter syndrome) that helps in improving the course of diseases by reducing the somatic symptoms, including hepatomegaly and splenomegaly. In addition, as per the same source, ERT using human recombinant iduronate 2- sulfatase administered intravenously is considered the current standard of care for patients with Hunter syndrome.

Browse 30 Market Data Tables and 24 Figures spread through 180 Pages and in-depth TOC on “Global Mucopolysaccharidosis (MPS) Treatment Market”- Forecast to 2030, Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/mucopolysaccharidosis-treatment-market-4184

Key Takeaways of the Global Mucopolysaccharidosis (MPS) Treatment Market :

• The global mucopolysaccharidosis (MPS) treatment market is expected to exhibit a CAGR of 10.1% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global mucopolysaccharidosis (MPS) treatment market.
• By MPS Type, the MPS-I segment is expected to hold a dominant position in the global mucopolysaccharidosis (MPS) treatment market during the forecast period, and this is attributed to the increasing approval for enzyme replacement therapy for mucopolysaccharidosis (MPS) treatment. For instance, in October 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, received Brazil’s National Health Surveillance Agency (ANVISA) approval for its Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPS VII, Sly syndrome) for patients of all ages.
• By Region, North America is expected to be the dominant region in the global mucopolysaccharidosis (MPS) treatment market, owing to the fact that the key players are focusing on inorganic strategies such as partnerships. In October 2020, Sanofi S.A., a France multinational pharmaceutical and healthcare company, and PerkinElmer, Inc., a company that enables scientists, researchers, and clinicians to address its most critical challenges across science and healthcare, collaborated in order to develop a 'Lantern Project' to provide a no-cost testing program for patients in the U.S. who suffer from specific types of lysosomal storage disorders (LSDs). Therefore, the Latern Project will arrange screening as well as confirmatory DNA testing and phlebotomy services for the patients suspected to be suffering from Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis type I (MPS I), or acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B.
• Major players operating in the global mucopolysaccharidosis (MPS) treatment market include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.